Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design

Xiaoyan Chen; Danfeng Zhang; Jiapeng Xue; Zhi Li

doi:10.1007/s12672-025-03083-0

Selective targeting of the AKT1 (E17K) mutation: advances in precision oncology and therapeutic design

Discov Oncol. 2025 Jul 3;16(1):1257. doi: 10.1007/s12672-025-03083-0.

Authors

Xiaoyan Chen^#^{1

2}, Danfeng Zhang^#³, Jiapeng Xue⁴, Zhi Li^{5

6}

Affiliations

¹ Department of Physical Therapy, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
² Medical College of Nanchang Institute of Technology, Nanchang, 330044, Jiangxi Province, China.
³ Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
⁴ Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China. Jiapengxue@taihehospital.com.
⁵ Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China. 12023202@shutcm.edu.cn.
⁶ Taihe Hospital, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Hubei University of Medicine, Shiyan, 442000, China. 12023202@shutcm.edu.cn.

^# Contributed equally.

PMID: 40608215
DOI: 10.1007/s12672-025-03083-0

Abstract

The AKT1 (E17K) mutation, associated with unfavourable outcomes in solid tumours, promotes cancer proliferation and persistence. A recent study by Gregory et al. discovered a reversible covalent inhibitor targeting this mutation, exhibiting significant anti-tumor action with little effects on normal cells. This advancement provides a targeted therapeutic approach for AKT-mutant malignancies and informs further inhibitor research.

Publication types

Letter